World Pharma Today

  All4Labels Global Packaging Group , a global leader in digital and sustainable labeling solutions, has undertaken a significant expansion of its operations in South Africa. The Group has made strategic investments in infrastructure and technology to enhance its services in the region, marking a milestone in the company’s growth strategy. With the acquisition of a production  site in Durban  18 months ago, All4Labels expanded its market presence in South Africa. Since then, the Group has successfully integrated the facility into its global network, ensuring it aligns with the company’s high standards and operational policies. With this integration now being completed, the site will play a key role in advancing the company’s labeling services in the South African market. The South African region is strategically important for All4Labels as part of its broader growth objectives. The Group is committed to delivering outstanding value to its customers, currently served in th...

  Drug development is a long and complex process that starts with discovery and, if successful, ends with government approval for marketing. Each step in the drug development process, outlined below, has specific goals with the aim of down-selecting appropriate hits and candidates to an approved drug substance. Here, we discuss the relevant objectives and techniques used in each stage of antibody drug development. Discovery The discovery phase is broken down into early and late-stage discovery. The primary goal of the discovery stages is to remove any sequence with undesired performance considering both chemical instabilities and target binding. Discovery will start with a large panel of antibodies that may range from hundreds to thousands and be reduced to a pool in the tens. To reduce the panel, in silico screening is commonly used as a primary tool because sample availability is very scarce at this stage. In silico screening uses computer simulations or virtual screening tools t...

  [LEIDEN, NL] – Life Science Newswire – Synexa Life Sciences, a global provider of biomarker and bioanalytical solutions to the pharmaceutical, biotech, and CRO industries, has proudly achieved the My Green Lab Certification at the highest ‘Green’ level at its Cape Town, South Africa facility. Laboratories play a crucial role in advancing healthcare but are among the most resource-intensive environments in the life sciences industry. Synexa is committed to implementing and enhancing sustainability practices throughout the organisation, without any compromise on quality or scientific excellence. Achieving the My Green Lab Certification at the ‘Green’ level will enable Synexa to further support the increasing customer demand for ethical and environmentally conscious clinical studies. The certification process, which commenced in 2024, involved implementing numerous sustainability measures across various departments including lab operations, research practices, supply chain, procurem...